Prognostic factors for survival in esophageal squamous cell carcinoma (ESCC) patients with a complete regression of the primary tumor (ypTO) after neoadjuvant chemoradiotherapy (NCRT) followed by surgery

被引:7
|
作者
Kong, Min [1 ,2 ,3 ]
Shen, Jianfei [2 ]
Zhou, Chao [4 ]
Yang, Haihua [4 ]
Chen, Baofu [1 ,2 ,3 ]
Zhu, Chengchu [2 ]
Wang, Gongchao [1 ]
机构
[1] Shandong Univ, Shandong Prov Hosp, Dept Thorac Surg, Cheeloo Coll Med, 9677 Jingshi Rd, Jinan, Peoples R China
[2] Wenzhou Med Univ, Dept Cardiothorac Surg, Taizhou Hosp Zhejiang Prov, Taizhou, Peoples R China
[3] Taizhou Enze Med Ctr Grp, Enze Hosp, Dept Cardiothorac Surg, Taizhou, Peoples R China
[4] Wenzhou Med Univ, Dept Radiotherapy, Taizhou Hosp Zhejiang Prov, Taizhou, Peoples R China
关键词
Esophageal squamous cell carcinoma (ESCC); neoadjuvant chemoradiation; esophagectomy; prognostic factors; PREOPERATIVE CHEMORADIATION; COMPLETE RESPONSE; CANCER; EDITION;
D O I
10.21037/atm-20-4864
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: There are also differences in survival prognosis among esophageal squamous cell carcinoma (ESCC) patients with a complete regression of the primary tumor (ypT0) after Neoadjuvant chemoradiotherapy (NCRT) followed by surgery. And the purpose of this study was to investigate influencing factors from these different prognostic outcomes and their possible causes. Methods: The clinical data of 88 cases of ESCC patients with ypT0 after NCRT followed by surgery between 2011 and 2019 were retrospectively analyzed. The clinical and pathological prognostic factors that affect the survival were analyzed. Results: Sex, number of lymph nodes dissected, and pathologic positivity of lymph nodes may be significant in univariate analysis (P<0.1). Further multivariate analysis suggested that the pathologic positivity of the lymph nodes was an independent factor affecting prognosis (HR: 4.757, 95% CI: 2.195-10.313, P=0.000). Subsequently, the whole group was divided into a positive lymph node group (group LN+) and a negative lymph node group (group LN-) for comparison. The overall survival (OS) of group LN+ was significantly worse (HR: 0.211, 95% CI: 0.0336-0.239; P<0.0001), and recurrence-free survival (RFS) was significantly poorer in the LN+ group (HR: 0.0679, 95% CI: 0.0239-0.1923, P<0.0001). There were 14 cases of recurrence and metastasis in the LN+ group (14/21, 66.7%) and 10 cases in the group LN- (10/67, 14.9%). Among the sites of recurrence and metastasis, there were 10 (10/14, 71.4%) and 4 (4/14, 28.6%) cases of distant metastasis, respectively, and 4 (4/14, 28.6%) cases of local metastasis in the LN+ group; meanwhile, there were 8 (8/10, 80.0%) cases of distant metastasis and 2 (2/10, 20.0%) cases of local metastasis in the LN- group. Conclusions: The independent risk factor for survival prognosis in ESCC patients with ypT0 after NCRT followed by surgery was positive postoperative pathological lymph nodes. The reason for the shortened survival time associated with this group of patients was their susceptibility to recurrence and metastasis.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Circulating tumor DNA (ctDNA) in predicting residual disease after neoadjuvant chemoradiotherapy (nCRT) for esophageal squamous cell carcinoma (ESCC).
    Liu, Zhichao
    Yang, Yang
    Liu, Jun
    Zhu, Li
    Yu, Hong
    Zhu, Mingjun
    Yang, Xi Li Jie
    Xiang, Jianxing
    Li, Haiyan
    Li, Bing
    Li, Zhigang
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Evaluation of Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery
    Yoichi Hamai
    Jun Hihara
    Manabu Emi
    Takaoki Furukawa
    Yuji Murakami
    Ikuno Nishibuchi
    Yuta Ibuki
    Ichiko Yamakita
    Tomoaki Kurokawa
    Yasushi Nagata
    Morihito Okada
    [J]. World Journal of Surgery, 2018, 42 : 1496 - 1505
  • [3] Evaluation of Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery
    Hamai, Yoichi
    Hihara, Jun
    Emi, Manabu
    Furukawa, Takaoki
    Murakami, Yuji
    Nishibuchi, Ikuno
    Ibuki, Yuta
    Yamakita, Ichiko
    Kurokawa, Tomoaki
    Nagata, Yasushi
    Okada, Morihito
    [J]. WORLD JOURNAL OF SURGERY, 2018, 42 (05) : 1496 - 1505
  • [4] Prognostic significance of tumor regression grade for patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery
    Hatogai, Ken
    Fujii, Satoshi
    Kojima, Takashi
    Daiko, Hiroyuki
    Kadota, Tomohiro
    Fujita, Takeo
    Yoshino, Takayuki
    Doi, Toshihiko
    Takiguchi, Yuichi
    Ohtsu, Atsushi
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2016, 113 (04) : 390 - 396
  • [5] Prognostic Factors for Patients With Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy Followed by Surgery
    Kitasaki, Nao
    Hamai, Yoichi
    Emi, Manabu
    Kurokawa, Tomoaki
    Yoshikawa, Toru
    Hirohata, Ryosuke
    Ohsawa, Manato
    Okada, Morithito
    [J]. IN VIVO, 2022, 36 (06): : 2852 - 2860
  • [6] Personalized circulating tumor DNA (ctDNA) analysis in predicting residual disease after neoadjuvant chemoradiotherapy (nCRT) for esophageal squamous cell carcinoma (ESCC)
    Liu, Zhichao
    Yang, Yang
    Liu, Jun
    Zhang, Hong
    Yu, Hong
    Han, Yuchen
    Fu, Xiao-Long
    Zhang, Hao
    Xiang, Jianxing
    Chen, Songan
    Li, Xi
    Zhu, Mingjun
    Li, Zhigang
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Prognostic Impact of Inflammation-Based Factors in Patients with Esophageal Squamous Cell Carcinoma Achieving Pathological Complete Response After Neoadjuvant Chemoradiotherapy Followed by Surgery
    Kim, Ji Yong
    Yun, Jea Kwang
    Kim, Yong-Hee
    Park, Seung-il
    Lee, Jeong Hoon
    Jung, Hwoon-Yong
    Lee, Gin Hyug
    Song, Ho June
    Kim, Do Hoon
    Choi, Kee Don
    Ahn, Ji Yong
    Kim, Sung-Bae
    Cho, Kyung-Ja
    Ryu, Jin-Sook
    Kim, Jong Hoon
    Kang, Jihoon
    Park, Sook Ryun
    Kim, Hyeong Ryul
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2024,
  • [8] The Role of Adjuvant Chemotherapy after Neoadjuvant Chemoradiotherapy Followed by Surgery in Patients with Esophageal Squamous Cell Carcinoma
    Park, Seong Yong
    Kim, Hong Kwan
    Jeon, Yeong Jeong
    Lee, Junghee
    Cho, Jong Ho
    Choi, Yong Soo
    Shim, Young Mog
    II Zo, Jae
    [J]. CANCER RESEARCH AND TREATMENT, 2023, 55 (04): : 1231 - 1239
  • [9] A Survival Prediction Nomogram for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery
    Ding, Tianyan
    Liu, Cantong
    Huang, Binliang
    Chu, Lingyu
    Wei, Laifeng
    Lin, Yiwei
    Luo, Yun
    Zhang, Biao
    Hong, Chaoqun
    Xu, Yiwei
    Peng, Yuhui
    [J]. CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 7771 - 7782
  • [10] Safety of Neoadjuvant Chemoradiotherapy Followed by Surgery for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
    Herbella, Fernando A. M.
    Patti, Marco G.
    [J]. JAMA SURGERY, 2021, 156 (05) : 452 - 452